Mahendra G. Shah, PhD, Chairman of the Board
Dr. Shah is a venture partner at Vivo Ventures, a health-care focused venture capital firm. He was the founder, chairman, and CEO of NextWave pharmaceuticals, a pediatric focused specialty pharmaceutical company. Prior to founding NextWave Pharmaceuticals, Dr. Shah was the chairman and CEO of First Horizon Pharmaceuticals, which was sold to Shionogi Pharmaceuticals for $1.4B. He had served on the board of Unimed Pharmaceuticals, Introgen Therapeutics, Inpharmakon, Protomed, Structural Bioinformatics, and Zarix. Dr. Shah had also held various scientific and managerial roles in Fujisawa USA (Astellas), Schering-Plough and Bristol Myer-Squibb. Dr. Shah received his BS degree in Pharmacy from LM College of Pharmacy in Gujarat, India, and his PhD degree in Industrial Pharmacy from St Johns’s University.
Stuart J. M. Collinson, PhD, MBA
Dr. Collinson is a partner at Forward Ventures. Dr. Collinson is a director of Affinium Pharmaceuticals Inc., Asteres Inc., Sequel Pharmaceuticals Inc., Tioga Pharmaceuticals Inc. and Vertex Pharmaceuticals Inc. Previously he was Chairman, Chief Executive Officer and President of Aurora Biosciences Corporation (acquired by Vertex Pharmaceuticals Inc. for $600 million). Before Aurora, Dr. Collinson was Chief Executive Officer of privately held Andaris Limited (acquired by Quadrant plc, now part of Elan Corporation PLC). He held senior management positions at GlaxoWellcome PLC (now GlaxoSmithKline PLC) and Baxter International Inc., and was a consultant with The Boston Consulting Group.
Jim Glasheen, PhD
Dr. Glasheen is a general partner with Technology Partners. He joined Technology Partners from CIT Venture Capital, where he served as Managing Director, leading the Group’s efforts in Life Science investing. Previously, he was a leader within McKinsey & Company’s Pharmaceutical and Medical Products Practice. Dr. Glasheen is on the Advisory Council of the Entrepreneurial Center at the University of California, Berkeley.
Richard C. Pasternak, MD
Dr. Pasternak retired from Merck in 2011. During his tenure at Merck, Dr. Pasternak was the Vice President, Clinical Research, leading the Cardiovascular/Atherosclerosis Clinical Research Department, and later was the Vice President, Head of Global Scientific Affairs and Scientific Leadership. He also chaired the R & D oversight committee for the Merck-Schering Plough Joint Venture on drug development for hypercholesterolemia. Prior to joining Merck, Dr. Pasternak was the Director of Preventive Cardiology and Cardiac Rehabilitation at the Massachusetts General Hospital, and an Associate Professor of Medicine at Harvard Medical School. As a faculty member of the Harvard Medical School, he was the Director of Coronary Care Unit at Beth Israel Hospital, and later established a new Section of Preventive Cardiology at Massachusetts General Hospital. Dr. Pasternak earned his BA and MD degrees from Yale University.
Alain Baron, MD
Dr. Baron is founding CEO of Elcelyx. He is also a clinical advisor to Essentialis. Prior to founding Elcelyx, he was Senior Vice President for Research at Amylin Pharmaceutical. He had previously served in various senior clinical roles at Amylin. Prior to Amylin Pharmaceutical, Dr. Baron was Professor of Medicine and Director of the Division of Endocrinology and Metabolism, Department of Medicine, Indiana University School of Medicine.